Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma
Wei Guo(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Jie He(Chinese Academy of Medical Sciences & Peking Union Medical College), Lei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Sijin Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Qilin Huai(Chinese Academy of Medical Sciences & Peking Union Medical College), Yibo Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Song Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuemin Xue(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 4
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding
|Nature Communications|2021|193
WNT/β-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis
|Cell Death and Disease|2021|171
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
|Annals of Oncology|2013|126
Consensus for HER2 alterations testing in non-small-cell lung cancer
|ESMO Open|2022|110